Google+ Facebook Twitter Twitter

Review, refresh and reimagine

A look back at how the Blood Stocks Management Scheme has evolved over the last two decades, some recent achievements, and what is planned for the next 20 years.

The Blood Stocks Management Scheme (BSMS) was established in April 2001, as a partnership between hospital blood transfusion laboratories and the then National Blood Service (NBS) upon request of the Department of Health, not only to maximise the use of donated blood, but to develop a deeper understanding of blood inventory management across the whole supply chain, which up to that point was largely held locally and unknown at the national level.

The scheme collects hospital red cell stock data, component issues and wastage data, together with blood centre stock levels and wastage, to support demand forecasting, identify trends and focus on wastage reduction. Analysis and reporting of hospital data encourages performance monitoring between peers, highlights good practice and has been pivotal for setting new key performance indicators. 

Please click here to read the full article

Image credit | Getty

Related Articles

The neonatal blood film

As at any other time in life, examination of a blood film in a neonate can be very informative. It is important that films are interpreted in the context of the clinical details and the blood count. It is also necessary to consider the period of gestation of the neonate at birth, since what is normal differs in term and preterm babies, particularly for those born before 28 weeks’ gestation.

My lab: a busy multi-site facility

Biomedical Scientist Team Leader Liam Morrissey gives a guided tour of blood sciences at the University Hospitals of Leicester NHS Trust.

Covid-19 and haemostasis screening: the expected and the unexpected

Senior Biomedical Scientist Clare Wigley and colleagues take us through how their lab processes and workflow changed during the waves of the COVID-19 pandemic.

Just my type: can blood type affect personality?

Senior Lecturer in Biomedical Science at the University of Sunderland Martin Maley explores the issues and puts a theory to the test.